肝脏疾病细胞铁死亡研究进展*

doi:10.3969/j.issn.1672-5069.2022.03.037

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (3): 449-452.doi: 10.3969/j.issn.1672-5069.2022.03.037

肝脏疾病细胞铁死亡研究进展^*

薛旗, 徐琊芸综述, 李婕审校

250021 济南市山东第一医科大学附属省立医院感染病科

收稿日期:2021-06-21 出版日期:2022-05-10 发布日期:2022-05-17
通讯作者: 李婕,E-mail:lijier@sina.com
作者简介:薛旗,女,26岁,硕士研究生。E-mail:xueqi_0522@163.com
基金资助:
^*国家自然科学基金面上项目(编号:81970545/82170609);山东省自然科学基金重点项目(编号:ZR2020KH006);济南市科技发展计划项目(编号:202019079)

Ferroptosis in chronic liver diseases

Xue Qi, Xu Yayun, Li Jie

Department of Infectious Disease, Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China

Received:2021-06-21 Online:2022-05-10 Published:2022-05-17

摘要/Abstract

摘要： 目的铁死亡是一种新发现的细胞死亡方式,是由于细胞内铁离子水平异常升高,导致氧化还原失衡,细胞膜发生脂质过氧化,最终细胞膜破裂,导致细胞死亡。目前认为铁死亡的中心环节是铁代谢和活性氧代谢。铁死亡可以影响多种疾病的发生发展过程,例如神经退行性疾病、肿瘤、缺血再灌注损伤、免疫性疾病等。越来越多的研究表明,在多种肝脏疾病的发生发展过程中均出现不同程度的铁超载和脂质活性氧堆积等铁死亡特征。铁死亡可以通过调节细胞内铁离子水平和脂质过氧化程度影响肝脏疾病的进程。本文将针对肝脏疾病发病过程中细胞铁死亡研究进展进行综述。

关键词: 肝脏疾病, 铁死亡, 脂质过氧化, 活性氧

Abstract: Objective Ferroptosis is a newly discovered mode of cell death, which is caused by the abnormal increase of intracellular iron ion levels, resulting in the imbalance of redox, lipid peroxidation of cell membrane, and finally cell death owing to cell membrane rupture. At present, the central link of ferroptosis is iron metabolism and reactive oxygen metabolism. Ferroptosis can affect the occurrence and development of a variety of diseases, such as neurodegenerative diseases, tumors, ischemia-reperfusion injury, immunoimbalance diseases, etc. Increasing numbers of studies have shown that the characteristics of ferroptosis, such as iron overload and accumulation of lipid reactive oxygen species, occur in the development many liver diseases. Ferroptosis can affect the progression of liver diseases by regulating the intracellular iron ion levels and lipid peroxidation degree.In this review, we put emphasis on the research progress of ferroptosis in liver diseases.

Key words: Liver diseases, Ferroptosis, Lipid peroxidation, Reactive oxygen species

薛旗, 徐琊芸, 李婕. 肝脏疾病细胞铁死亡研究进展^*[J]. 实用肝脏病杂志, 2022, 25(3): 449-452.

Xue Qi, Xu Yayun, Li Jie. Ferroptosis in chronic liver diseases[J]. Journal of Practical Hepatology, 2022, 25(3): 449-452.

参考文献

[1] Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2019, 4(5):389-398.
[2] 廖志武,王善青.我国2000-2019年主要热带病的流行与防治概况.中国热带医学, 2020, 20(3):193-201.
[3] 刘岩,苏琳.酒精性肝病基层诊疗指南(2019年). 临床肝胆病杂志, 2021, 37(1):36-40.
[4] 崔天盆,郑承红,陈杰,等. 细胞死亡方式及其清除. 中国免疫学杂志, 2014, 30(6):843-846.
[5] Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 2012, 149(5):1060-1072.
[6] Yang WS, Kim KJ, Gaschler MM, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A, 2016, 113(34):E4966-4975.
[7] Santana-Codina N, Mancias JD. Therole of NCOA4-mediated ferritinophagy in health and disease. Pharmaceuticals (Basel), 2018, 11(4):232-236.
[8] Hu CL, Nydes M, Shanley KL, et al. Reduced expression of the ferroptosis inhibitor glutathione peroxidase‐4 in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurochem, 2019, 148(3):426-439.
[9] Bridges RJ, Natale NR, Patel SA. System xc(-) cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol, 2012, 165(1):20-34.
[10] Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol, 2019, 12(1):34.
[11] Buijs M, Doan NT, Van Rooden S, et al. In vivo assessment of iron content of the cerebral cortex in healthy aging using 7-Tesla T2-weighted phase imaging. Neurobiol Aging, 2017, 53:20-26.
[12] Hu Z, Zhang H, Yang SK, et al. Emergingrole of ferroptosis in acute kidney injury. Oxid Med Cell Longev, 2019, 2019:8010614.
[13] Tsurusaki S, Tsuchiya Y, Koumura T, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis, 2019, 10(6):341-349.
[14] Qi J, Kim JW, Zhou Z, et al. Ferroptosisaffects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice. Am J Pathol, 2020, 190(1):68-81.
[15] Li X, Wang TX, Huang X, et al. Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity. Liver Int, 2020, 40(6):1378-1394.
[16] Yang Y, Chen J, Gao Q,et al. Study on the attenuated effect of ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease. Toxicology, 2020, 445:152599.
[17] 王兆飞,管世鹤,陈礼文,等. 慢性乙型肝炎患者血清铁调素和铁代谢指标及体外 HBV 转染 Huh7 细胞铁调素水平变化. 实用肝脏病杂志, 2020, 23(2):183-186.
[18] Kuo CY, Chiu V, Hsieh PC, et al. Chrysophanol attenuates hepatitis B virus X protein-induced hepatic stellate cell fibrosis by regulating endoplasmic reticulum stress and ferroptosis. J Pharmacol Sci, 2020, 144(3):172-182.
[19] Pan Y, Tang P, Cao J, et al. Lipid peroxidation aggravates anti-tuberculosis drug-induced liver injury: Evidence of ferroptosis induction. Biochem Biophys Res Commun, 2020, 533(4):1512-1518.
[20] Lörincz T, Jemnitz K, Kardon T, et al. Ferroptosis is involved in acetaminophen induced cell death. Pathol Oncol Res, 2015, 21(4):1115-1121.
[21] Wang M, Liu CY, Wang T, et al. (+)-Clausenamide protects against drug-induced liver injury by inhibiting hepatocyte ferroptosis. Cell Death Dis, 2020, 11(9):781.
[22] Zhou Z, Ye TJ, DeCaro E, et al. Intestinal SIRT1deficiency protects mice from ethanol-induced liver injury by mitigating ferroptosis. Am J Pathol, 2020, 190(1):82-92.
[23] Zhou Z, Ye TJ, Bonavita G, et al. Adipose-specific lipin-1 overexpression renders hepatic ferroptosis and exacerbates alcoholic steatohepatitis in mice. Hepatol Commun, 2019, 3(5):656-669.
[24] Zhang Z, Yao Z, Wang L, et al. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells. Autophagy, 2018, 14(12):2083-2103.
[25] Sui M, Jiang X,Chen J, et al. Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway. Biomed Pharmacother, 2018, 106:125-133.
[26] Wang L, Zhang Z, Li M, et al. P53-dependent induction of ferroptosis is required for artemether to alleviate carbon tetrachloride-induced liver fibrosis and hepatic stellate cell activation. IUBMB Life, 2019, 71(1):45-56.
[27] Kong Z, Liu R, Cheng Y. Artesunate alleviates liver fibrosis by regulating ferroptosis signalingpathway. Biomed Pharmacother, 2019, 109:2043-2053.
[28] Li Y, Jin C, Shen M, et al. Iron regulatory protein 2 is required for artemether -mediated anti-hepatic fibrosis through ferroptosis pathway. Free Radic Biol Med, 2020, 160:845-859.
[29] Kim H, Lee JH, Park JW. Down-regulation of IDH2 sensitizes cancer cells to erastin-induced ferroptosis. Biochem Biophys Res Commun, 2020, 525(2):366-371.
[30] Wang S, Li F, Qiao R, et al. Arginine-rich manganese silicate nanobubbles as a ferroptosis-inducing agent for tumor-targeted theranostics. ACS Nano, 2018, 12(12):12380-12392.
[31] Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology, 2016, 63(1):173-184.
[32] Bai T, Lei P, Zhou H, et al. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells. J Cell Mol Med, 2019, 23(11):7349-7359.
[33] Zhang X, Du L, Qiao Y, et al. Ferroptosis is governed by differential regulation of transcription in liver cancer. Redox Biol, 2019, 24:101211.

肝脏疾病细胞铁死亡研究进展^*

Ferroptosis in chronic liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

本文评价

[1]	李亚萍, 翟嵩, 王媛, 邓江, 吴凤萍, 王沐淇, 贾晓黎, 李梅, 党双锁. 咖啡酸苯乙基酯缓解L02细胞脂毒性机制研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 786-789.
[2]	陈慧婷, 周永健. 肠道微生态影响肝脏疾病的若干进展与思考^*[J]. 实用肝脏病杂志, 2020, 23(6): 765-768.
[3]	麦静愔, 陈天阳, 平键, 成扬, 陈建杰. MiR-384对HFFA诱导的Hepa1-6细胞sirt3/FOXO1信号通路的影响^*[J]. 实用肝脏病杂志, 2018, 21(6): 829-832.
[4]	汪登斌. 肝脏疾病影像学诊断技术新进展[J]. 实用肝脏病杂志, 2018, 21(4): 489-492.
[5]	李珊珊, 洪丰综述, 陈煜审校. 干细胞治疗肝脏疾病研究进展^*[J]. 实用肝脏病杂志, 2018, 21(1): 145-148.
[6]	崔丹，杨宝山. Nrf2信号通路与肝细胞凋亡研究进展[J]. 实用肝脏病杂志, 2016, 19(3): 365-368.
[7]	袁平戈. 瞬时弹性成像技术在肝病诊断中的应用进展[J]. 实用肝脏病杂志, 2016, 19(1): 4-7.
[8]	张纯林,罗福成,童清平. 超声弹性成像在肝脏疾病中的应用[J]. 实用肝脏病杂志, 2010, 13(6): 456-459.
[9]	晁康, 龚晓蓉, 陈湖, 钟碧慧. Th17细胞在肝脏疾病中的免疫病理作用[J]. 实用肝脏病杂志, 2010, 13(3): 224-226.
[10]	陈耀凯, 郭艳. 脂肪源性间充质干细胞与肝病[J]. 实用肝脏病杂志, 2010, 13(1): 69-71.
[11]	秦艳, 张晾, 潘杰. 高脂饮食对非酒精性脂肪肝影响机制研究进展[J]. 实用肝脏病杂志, 2010, 13(1): 72-74.